title: Empagliflozin/metformin (Synjardy) for type 2 diabetes.
mesh_terms: D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D004338:Drug Combinations; D016527:Drug Costs; D004347:Drug Interactions; D005960:Glucosides / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D008687:Metformin / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D018579:Patient Selection; D018570:Risk Assessment; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D016896:Treatment Outcome
chemical_list: D001559:Benzhydryl Compounds; D015415:Biomarkers; D001786:Blood Glucose; D004338:Drug Combinations; D005960:Glucosides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C089180:SLC5A2 protein, human; C517652:hemoglobin A1c protein, human; C570240:empagliflozin